By supporting Immunodeficiency UK you are playing a key role in our mission

Kaza et al. performed an extensive longitudinal single-cell RNA-seq and plasma proteomic analysis of SIV-infected rhesus macaques on antiretroviral therapy (ART). Immune remodeling continues while on ART, despite near-complete viral suppression. Unique characteristics were identified in gut-associated lymphoid tissue and bone marrow, with implications for reservoir persistence and inflammation-included aging.

A gift to Immunodeficiency UK in your will could make all the difference. When people leave a gift in their Will, they continue to help long after they’re gone.

Every purchase from our online shop helps us continue supporting people living with primary and secondary immunodeficiency through trusted information, advocacy, awareness and support services.

STAT3 with a patient-derived substitution causes immune dysfunction by sequestering wild-type STAT3.

As a person or family affected by primary immunodeficiency, use this free step-by-step guide to determine which health benefits you use, compare health insurance plans, and choose the best private, Me...

Kaza et al. performed an extensive longitudinal single-cell RNA-seq and plasma proteomic analysis of SIV-infected rhesus macaques on antiretroviral therapy (ART). Immune remodeling continues while on ...

People with substance use disorders (SUDs) living with human immunodeficiency virus (HIV) experience overlapping structural and clinical barriers to care. Long-acting injectable antiretroviral therapy (LAI-ART) may improve treatment adherence and may strengthen engagement in health services. Whether initiation of LAI-ART is associated with subsequent uptake of medications for opioid use disorder (MOUD) is unknown.MethodsWe conducted a retrospective descriptive cohort study of people with HIV and a history of a SUD who initiated long-acting cabotegravir-rilpivirine (LA-CAB + RPV) at a low-barrier social services and public health organization between February 1, 2022 and June 30, 2025 and received at least 6 months of follow-up. We evaluated whether initiation of this regimen improved HIV and SUD outcomes, including uptake of MOUD, sustained treatment engagement, reduced opioid use, and viral suppression.ResultsForty patients initiated LA-CAB + RPV. Viral suppression improved from 73% at baseline to 98% at follow-up. Adherence was high, with only one missed scheduled dose and no recorded deaths from HIV-related causes. At baseline, 81.1% reported active opioid use and 32.4% were receiving medications for OUD. MOUD utilization increased to 78.4% at 6 months and 89.2% at end follow-up, while opioid use declined to 59.5% and 48.6%. Among those initiating medications for OUD after CAB + RPV, 90.9% remained on treatment, with 40% initiating within 2 months. Most patients remained engaged in HIV care.ConclusionsIntegrated low-barrier care models may improve continuity of care for marginalized populations.

A gift to Immunodeficiency UK in your will could make all the difference. When people leave a gift in their Will, they continue to help long after they’re gone.

Every purchase from our online shop helps us continue supporting people living with primary and secondary immunodeficiency through trusted information, advocacy, awareness and support services.

A gift to Immunodeficiency UK in your will could make all the difference. When people leave a gift in their Will, they continue to help long after they’re gone.

A person infected with the Human Immunodeficiency Virus (HIV) lost an administrative lawsuit challenging the rejection of their disability ... View article...